Your browser doesn't support javascript.
loading
[New Complement Therapeutics in Complement-Related Diseases].
Wakamiya, Nobutaka; Ohtani, Katsuki; Hidaka, Yoshihiko; Inoue, Norimitsu.
Afiliação
  • Wakamiya N; Department of Medicine and Physiology, Rakuno Gakuen University.
Brain Nerve ; 71(6): 555-564, 2019 Jun.
Artigo em Japonês | MEDLINE | ID: mdl-31171752
ABSTRACT
The complement was named after "a complement", a protein molecule that supports an antibody. It was considered previously that the complement mainly participates in protecting against microbial infections. But later, as research on biological functions in complement activation advanced drastically, it was elucidated that the complement could be involved in the onset of various diseases. In 2007, eculizumab (ECZ), an anti-C5 (complement factor 5) monoclonal antibody, was approved as a drug for paroxysmal nocturnal hemoglobinuria (PNH) in the United States. In Japan, ECZ was approved for PNH and atypical hemolytic uremic syndrome (aHUS) in 2010 and 2013, respectively. The success of ECZ created an opportunity for drug companies to develop new therapeutics targeting the complement system; development of complement therapeutics is now a major venture of pharmaceutical companies worldwide. Here, I will provide an outline of the approved complement therapeutics and those that are in development and clinical trial phase currently.
Assuntos
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Proteínas do Sistema Complemento / Inativadores do Complemento / Anticorpos Monoclonais Humanizados / Síndrome Hemolítico-Urêmica Atípica / Hemoglobinúria Paroxística Limite: Humanos País/Região como assunto: Ásia Idioma: Japonês Revista: Brain Nerve Assunto da revista: Cérebro / Neurologia Ano de publicação: 2019 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Proteínas do Sistema Complemento / Inativadores do Complemento / Anticorpos Monoclonais Humanizados / Síndrome Hemolítico-Urêmica Atípica / Hemoglobinúria Paroxística Limite: Humanos País/Região como assunto: Ásia Idioma: Japonês Revista: Brain Nerve Assunto da revista: Cérebro / Neurologia Ano de publicação: 2019 Tipo de documento: Artigo
...